DACA

[1]Padget K, et al. An investigation into the formation of N- [2- (dimethylamino) ethyl]acridine-4-carboxamide (DACA) and 6-[2- (dimethylamino) ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000;60 (6) :817-821.|[2]Dittrich C, et al. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer. 2003 Feb;39 (3) :330-4. |[3]Caponigro F, et al. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer. 2002 Jan;38 (1) :70-4. |[4]Twelves CJ, et al. Phase I and pharmacokinetic study of DACA (XR5000) : a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer. 1999 Aug;80 (11) :1786-91.